208 related articles for article (PubMed ID: 33336705)
21. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis type 2: A nationwide population-based study focused on survival after meningioma surgery.
Champeaux-Depond C; Weller J; Resche-Rigon M
Clin Neurol Neurosurg; 2020 Nov; 198():106236. PubMed ID: 33002675
[TBL] [Abstract][Full Text] [Related]
23. Clinical and economic burden of neurofibromatosis type 2 in the United States.
Koo AB; Yeung JT; Freedman IG; Lee JH; Ahmed OM; Ma AK; Miyagishima DF; DiLuna M; Kahle K
Clin Neurol Neurosurg; 2020 Oct; 197():106053. PubMed ID: 32683193
[TBL] [Abstract][Full Text] [Related]
24. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients.
Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870
[TBL] [Abstract][Full Text] [Related]
25. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
26. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.
Mautner VF; Baser ME; Thakkar SD; Feigen UM; Friedman JM; Kluwe L
J Neurosurg; 2002 Feb; 96(2):223-8. PubMed ID: 11838794
[TBL] [Abstract][Full Text] [Related]
27. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis 2.
Hoa M; Slattery WH
Otolaryngol Clin North Am; 2012 Apr; 45(2):315-32, viii. PubMed ID: 22483819
[TBL] [Abstract][Full Text] [Related]
29. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
30. Vestibular Schwannoma Excision in Sporadic versus Neurofibromatosis Type 2 Populations.
Mahboubi H; Maducdoc MM; Yau AY; Ziai K; Ghavami Y; Badran KW; Al-Thobaiti M; Brandon B; Djalilian HR
Otolaryngol Head Neck Surg; 2015 Nov; 153(5):822-31. PubMed ID: 25791708
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatosis type 2: growth stimulation of mixed acoustic schwannoma by concurrent adjacent meningioma: possible role of growth factors. Case report.
Pallini R; Tancredi A; Casalbore P; Mercanti D; Larocca LM; Consales A; Lauretti L; Fernandez E
J Neurosurg; 1998 Jul; 89(1):149-54. PubMed ID: 9647188
[TBL] [Abstract][Full Text] [Related]
32. Neurofibromatosis type 2.
Evans DG
Handb Clin Neurol; 2015; 132():87-96. PubMed ID: 26564072
[TBL] [Abstract][Full Text] [Related]
33. The genetic landscape and possible therapeutics of neurofibromatosis type 2.
Ghalavand MA; Asghari A; Farhadi M; Taghizadeh-Hesary F; Garshasbi M; Falah M
Cancer Cell Int; 2023 May; 23(1):99. PubMed ID: 37217995
[TBL] [Abstract][Full Text] [Related]
34. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
36. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
38. Neurofibromatosis 2.
Baser ME; R Evans DG; Gutmann DH
Curr Opin Neurol; 2003 Feb; 16(1):27-33. PubMed ID: 12544854
[TBL] [Abstract][Full Text] [Related]
39. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
40. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.
Picry A; Bonne NX; Ding J; Aboukais R; Lejeune JP; Baroncini M; Dubrulle F; Vincent C
Laryngoscope; 2016 Oct; 126(10):2358-62. PubMed ID: 27075822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
